Title: Feasibility of SARS-CoV-2 virus detection from consumer-grade cotton swabs

Running Title: Alternative swabs for COVID-19 screening

Keywords: COVID-19, SARS-CoV-2, RT-qPCR, swab, global health

Jeremiah J. Minich[1], Farhana Ali[2], Clarisse Marotz[3], Pedro Belda-Ferre[3], Leslie Chiang[4], Justin P.

Shaffer[3], Carolina S. Carpenter[5], Daniel McDonald[3], Jack Gilbert[3,5,6], Sarah M. Allard[3], Rob Knight[3,5,7,8],

Daniel A. Sweeney[9], Austin D. Swafford[5*]

1.   Marine Biology Research Division, Scripps Institution of Oceanography, University of California San

Diego, La Jolla, CA, USA.

2.   Division of Gastroenterology, Department of Pediatrics, University of California San Diego, La Jolla,

CA, USA.

3.   Department of Pediatrics, School of Medicine, University of California San Diego, La Jolla, CA,

USA.

4.   Division of Infectious Diseases, Department of Pediatrics, University of California San Diego, La

Jolla, CA, USA.

5.   Center for Microbiome Innovation, University of California San Diego, La Jolla, CA, USA.

6.   Scripps Institution of Oceanography, University of California San Diego, La Jolla, CA, USA.

7.   Department of Computer Science and Engineering, University of California San Diego, La Jolla, CA,

USA.

8.   Department of Bioengineering, University of California San Diego, La Jolla, CA, USA.

9.   Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine,

University of California, San Diego, La Jolla, CA, USA.

*Corresponding author: adswafford@ucsd.edu

Abstract

To control the growing COVID-19 pandemic, increased testing and containment is essential, yet clinical-

grade sampling supplies are expensive and rapidly being depleted. We demonstrate the feasibility of using

alternative consumer-grade swabs stored in 95% ethanol rather than viral transport media to detect SARS-

CoV-2 from ten hospitalized persons and hospital rooms.

Background

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) the causative agent of coronavirus disease 19 (COVID-19) has spread to 185 countries resulting in 278,892 deaths and 4,006,257 total confirmed cases as of May 11, 2020 [1-2]. Large-scale testing remains key for controlling viral spread, but sample collection supplies including swabs, viral transport media (VTM) and personal protective equipment (PPE) are being depleted in developed nations like the United States, and are in even shorter supply in low- and middle-income countries [3]. Validation of alternatives strategies such as self-administered testing using consumer-grade materials is urgently needed.

Concerns about consumer-grade materials include the presence of contaminant RNases and/or PCR inhibitors which would promote false negatives during evaluation for the presence of SARS-CoV-2 RNA by reverse transcription and quantitative polymerase chain reaction (RT-qPCR) as noted in the U.S. Centers for Disease Control (CDC) guidance for testing [4]. Similarly, the CDC-recommended VTM requires specialized ingredients and contains antimicrobials likely to interfere with downstream assessment of the microbial context of SARS-CoV-2 that may enable new insights into viral susceptibility and resistance [5]. VTM also maintains viral viability and therefore requires processing in a facility with more stringent biosafety practices compared to inactivating collection methods. Using inactivating sample collection solutions could increase the number of testing laboratories and ameliorate the risks associated with sample transport and processing. Here we demonstrate the feasibility of detecting SARS-CoV-2 RNA from patient and built-environment samples using viral-inactivating storage solutions and alternative medical-grade and consumer-grade swabs.

Methods

Swab feasibility testing

Six swab types were compared and processed following the standard SARS-CoV-2 protocol provided by the CDC [6] (Supplementary Methods). These swab types are: sterile polyester-head, plastic-shaft ('PE'),

sterile foam-head, plastic-shaft ('BDF'), non-sterile cotton-head, plastic-shaft ('TMI'), non-sterile cotton-

head plastic-shaft consumer-grade ('CGp'), non-sterile cotton-head wooden-shaft consumer-grade

('CGw'), and non-sterile cotton-head, wooden-shaft ('Pu'). Suppliers and part numbers are provided in

Supplementary Methods.

Patient and hospital environmental sampling

This study was performed with approval of the UC San Diego Institutional Review Board under protocols

#150275 and #200613. All study participants were diagnosed and hospitalized with COVID-19, and both

nasal samples and hospital surfaces were collected using three unmoistened swab types (PE, TMI, CGp)

immediately placed in a collection tube containing 95% EtOH and stored on dry ice. Collection details and

sample processing are provided in the Supplementary Methods.

Results:

We compared the efficiency of extracting and processing RNA from 200 µL of VTM eluent surrounding

polyester-tipped plastic-shafted nasopharyngeal (NP) swabs (CDC protocol) to more accessible nares

samples collected using PE swabs stored in viral-inactivating alcohol. RNA extraction efficiency was

significantly reduced from samples stored in 95% EtOH when extracted from the eluent (n=22), but similar

when extracted from the swab head itself (n=18) compared to the CDC protocol (n=39) (Figure 1a).

Extracting from the swab head also provided significantly higher SARS-CoV-2 viral load compared to the

EtOH eluent of the same patient samples (n=7) (Figure 1b, p=0.032). We separately compared the use of

95% EtOH vs 91% isopropanol as the storage media with human RNA and found no impact on extraction

efficiency (32.1% and 35.3% recovery respectively) (ANOVA, P>0.05) (Figure 1c). However, in the

presence of abundant RNase, 95% EtOH protected both human RNA and SARS-CoV-2 RNA better than

91% isopropanol (Figure 1d).

We next tested RNA recovery from a range of medical- and consumer-grade swabs (Supplementary

Methods). The yield was highest from swab heads compared to eluent regardless of the swab type and

whether stored in 95% EtOH ($P<0.0001$, U=37, Mann-Whitney) or 91% isopropanol ($P<0.0001$, U=28,

Mann-Whitney) (Figure 1e-f). The storage solution did not impact RNA quality (Supplemental Figure 1b,

Mann-Whitney, $P>0.05$), though swab type had a minor impact (Supplemental Figure 1c, Kruskal-Wallis

$P=0.0325$, KW=12.17) [6]. RNA recovery ratio of swab-to-eluent and total yield varied among swab type

($P<0.0001$, KW=28.37, Kruskal-Wallis for eluent, and $P<0.0001$, KW=15.43, Kruskal-Wallis for swab-

heads) (Supplemental Figure 2). CGp swabs had the highest recovery from the swab head, while TMI swabs

had the highest overall recovery of RNA from both eluent and direct swab extractions (Supplemental Figure

2). Swab type did not impact the ability to detect a linear decrease of positive control human and SARS-

CoV-2 RNA when extracting directly from either CDC-recommended PE swabs or CGp swabs

(Supplemental Figure 3).

As a clinical proof-of-concept, we collected samples from ten participants admitted to the hospital for

COVID-19 using TMI and/or CGp swabs alongside the recommended PE swabs, and performed RT-qPCR

per CDC guidelines. All three swab types successfully detected positive control SARS-CoV-2 RNA except

for one false negative CGp, and no false positives (Supplemental Figure 4). For this comparison, samples

inconclusive solely for the SARS-CoV-2 N2 amplicon (I-N2 in Figure 1g) were considered positive for the

presence of SARS-CoV-2 RNA based on observed and reported concerns with this primer set [7]. PE swabs

were 100% concordant with NP results when extracting from the swab head compared to 67% concordance

for eluent from the same samples. TMI swabs were 85% and 57% concordant while CGp were 70% and

56% concordant for swab head and eluent respectively (Figure 1g). To evaluate contamination of SARS-

CoV-2 RNA on environmental surfaces, we collected and compared swabs from the inside floor and bedrail

of the same participants' rooms using the same swab types [8]. Only 3/10 bedrails had detectable SARS-

CoV-2 with any swab type, while floor samples tested positive for SARS-CoV-2 RNA for at least one swab

type in 9/10 rooms (Figure 1g). Overall, the concordance between PE swabs was ~84% both for CGp

(25/30) and TMI (22/26) across participant and environmental samples (Figure 1d).

Discussion:

We provide evidence that nasal samples collected using more widely-available consumer-grade cotton-

tipped swabs can be stored in viral-inactivating alcohol without compromising the ability to detect SARS-

CoV-2. The sensitivity for detection of SARS-CoV-2 RNA was comparable between the hospital NP swabs

(CDC protocol) and both TMI and CGp nasal swabs when extracting from the swab head. Negative NP

results for previously positive participants may be due to viral clearance, the timing of sampling during the

course of infection or inconsistencies among the standard NP swabs. Of note, wooden-shafted swabs

performed poorly only when extracting from the eluent, suggesting that RNA adsorption onto the shaft

rather than RT-qPCR inhibitors may be the source of interference with current eluent-based testing

methods.

Cotton-tipped swabs and alcohol-based solutions are compatible with standard microbiome and

metabolome analyses prohibited by VTM, and could enable more widespread assessment for SARS-CoV-

2 RNA in human and environmental samples. SARS-CoV-2 was only detected on 30% of participants'

bedrails, which may have been due to routine cleaning measures and/or minimal interaction with the

surfaces from heavily-sedated or intubated patients. This may be present a challenge for monitoring shared

surfaces between the healthcare worker and patients. In contrast, the detection of SARS-CoV-2 RNA from

the floor samples demonstrates a potentially important reservoir for viral exposure, as shoe covers are note

currently recommended by the CDC. However, additional testing is needed to determine whether viable

virus remains on these surfaces.

In summary, our results suggest detection of SARS-CoV-2 RNA could be performed using less expensive,

consumer-grade materials. We add to the emerging body of literature supporting nasal sampling as opposed

to NP sampling [10–14]. It is conceivable that patients could collect samples at home, thus reducing risk

and saving the use of PPE for healthcare workers. Further confirmatory studies using consumer-grade swabs

would greatly support COVID-19 screening worldwide, particularly in resource-limited settings.

Funding:

This work was supported by the UC San Diego Center for Microbiome Innovation (CMI). JJM is supported

by the National Science Foundation Center for Aerosol Impacts on Chemistry of the Environment

#1801971. CM is supported by NIDCR NRSA F31 Fellowship 1F31DE028478-01. PBF is partially funded

through trainee support from Sanitarium Health and Wellbeing in partnership with the CMI. DM is partially

funded by support from Danone Nutricia Research in partnership with the CMI.

Acknowledgements:

We thank research participants who donated samples, the health care professionals who assisted in the

collection of samples, and Alison Vrbanac, Louis-Felix Nothias-Scaglia, and Shi Huang for assistance in

transportation and Dominic Nguyen for sampling kit preparation. This research benefited tremendously

from lessons learned and techniques developed in the Sloan Microbiology of the Built Environment (MoBE

program). We thank Stanley T. Motley for early discussion on nucleic acid stability, Sandrine Miller-

Montgomery for guidance in RT-qPCR analyses. We thank Thomas F. Rogers and Nathan Beutler for

providing the SARS-CoV-2 viral RNA used as a control in this study and David Pride for supplying samples

from NP swabs in VTM for our comparisons.

The authors have no conflict of interest related to the work described in this manuscript.

References:

1.   Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2.

Nat Med **2020**; 26:450–452.

2.   Coronavirus disease 2019 (COVID-19) Situation Report – 112. WHO, 2020. Available at:

https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200511-covid-19-sitrep-

112.pdf?sfvrsn=813f2669_2.

3.   Global coalition to accelerate COVID-19 clinical research in resource-limited settings. The Lancet.

2020; Available at: http://dx.doi.org/10.1016/s0140-6736(20)30798-4.

4.   Oropharyngeal 1., Swabs N. Collection of Upper Respiratory Tract Specimens. Available at:

https://www.cdc.gov/urdo/downloads/SpecCollectionGuidelines.pdf.

5.   Centers for Disease Control and Prevention. Centers for Disease Control and Prevention SOP#:

DSR-052-02- PREPARATION OF VIRAL TRANSPORT MEDIUM. 2020. Available at:

https://www.cdc.gov/coronavirus/2019-ncov/downloads/Viral-Transport-Medium.pdf. Accessed 24

April 2020.

6.   Schroeder A, Mueller O, Stocker S, et al. The RIN: an RNA integrity number for assigning integrity

values to RNA measurements. BMC Mol Biol **2006**; 7:3.

7.   Marx V. Coronavirus jolts labs to warp speed. Nat Methods **2020**; 17:465–468.

8.   van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and Surface Stability of SARS-CoV-2 as

Compared with SARS-CoV-1. N Engl J Med **2020**; 382:1564–1567.

9.   Pan Y, Zhang D, Yang P, Poon LLM, Wang Q. Viral load of SARS-CoV-2 in clinical samples.

Lancet Infect Dis **2020**; 20:411–412.

10.   Xie C, Lu J, Wu D, et al. False negative rate of COVID-19 is eliminated by using nasal swab test.

Travel Med Infect Dis **2020**; :101668.

11.   Yu F, Yan L, Wang N, et al. Quantitative Detection and Viral Load Analysis of SARS-CoV-2 in

Infected Patients. Clin Infect Dis **2020**; Available at: http://dx.doi.org/10.1093/cid/ciaa345.

12.   Petruzzi G, De Virgilio A, Pichi B, et al. COVID -19: Nasal and oropharyngeal swab. Head & Neck.

2020; Available at: http://dx.doi.org/10.1002/hed.26212.

13.   Péré H, Podglajen I, Wack M, et al. Nasal swab sampling for SARS-CoV-2: A convenient

alternative in time of nasopharyngeal swab shortage. Journal of Clinical Microbiology. 2020;

Available at: http://dx.doi.org/10.1128/jcm.00721-20.

14.   Tu Y-P, Jennings R, Hart B, et al. Patient-collected tongue, nasal, and mid-turbinate swabs for

SARS-CoV-2 yield equivalent sensitivity to health care worker collected nasopharyngeal swabs.

Available at: http://dx.doi.org/10.1101/2020.04.01.20050005.

15.   CDC. Coronavirus Disease 2019 (COVID-19). 2020. Available at:

https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-probes.html. Accessed 21 April

2020.

16.   CDC/DDID/NCIRD/ Division of Viral Diseases. CDC 2019-Novel Coronavirus (2019-nCoV) Real-

Time RT-PCR Diagnostic Panel. **2020**; Available at: https://www.fda.gov/media/134922/download.

Figure Legends

Figure 1. Validation of alternative swabs and storage buffer (95% EtOH and 91% isopropanol) in RNA recovery and detection of COVID-19.

a) Human RNAse P gene (Rp) RNA extraction control comparison across sample types. Clinical gold-standard polyester-tipped plastic-shaft NP swabs stored in VTM and extracted from 200 µL of eluent (left, n=39) have significantly lower higher copy numbers compared to 200 µL EtOH eluent from PE nares swabs (middle, n=22), but not when extracted from the EtOH-preserved swab head (right, n=18). One-way ANOVA with Tukey's multiple comparison VTM eluent vs EtOH eluent p=<0.001, EtOH eluent vs EtOH swab p<0.001, VTM vs EtOH swab p = 0.266. **b)** Extrapolated viral RNA copy number from nares samples collected with BD polyester swabs in the hospital stored in 95% EtOH and extracted from either the eluent or swab from the same sample(one-tailed paired Student's T-test p=0.032). **c)** Proportion of recovered RNA across three storage buffers: None, 95% EtOH, and 91% isopropanol (ns, ANOVA p>0.05). **d)** Evaluation of RNaseA inhibition by 95% EtOH (grey) and 91% isopropanol (blue) (multiple t-test) using either the human Rp or SARS-CoV-2 N1 primer set. **e)** Comparison human RNA recovery across six swab types (PE=polyester 'commercial', BDF=BD foam 'commercial', TMI=BD TMI 'commercial', CGp=plastic 'consumer grade', Pu=Puritan 'commercial', CGw=wood 'consumer grade'), extracted from 200µL eluent (blank bar) or the swab head. Recovery for each swab type is normalized to the CDC recommended method (eluent from PE swab). A '2' would indicate there was 2x more RNA recovered whereas a 0.5 would indicate a 50% reduction in RNA recovery. **f)** Total RNA copies per extraction for all samples which are grouped by sample-type (eluent or swab head) and storage buffer (95% EtOH or 91% isopropanol). Pairwise comparisons performed within sample-type (not significant) and across sample-type controlling for storage buffer (Mann-Whitney, U=test statistic). **g)** Demonstration of consumer-grade CGp and bulk TMI swab congruence compared to clinical-grade hospital tests using polyester-tipped plastic shafted NP swabs across ten patient rooms. Samples positive (+, dark blue background) or negative (-, orange background) for N1, N2, and Rp by CDC guidelines. Samples positive for N1 and Rp, but negative for N2 are labeled inconclusive for N2 (I-N2, blue) but

considered positive for comparisons. Samples positive for N2 and Rp, but negative for N1 (I-N1, light

blue) are inconclusive. Samples not measured for a given patient are labeled as NaN (light grey). (P<0.05

= *, P<0.01 = **, P<0.001 = ***, P<0.0001 = ****)

Figures

Figure 1. Validation of alternative swabs and storage buffer (95% EtOH and 91% isopropanol) in

RNA recovery and detection of COVID-19.

Supplementary Methods

VTM versus EtOH sample comparison

Nasopharyngeal (NP) swabs were collected according to CDC guidelines and stored in viral transport

media (VTM). For comparison, sterile polyester-head, plastic-shaft ('PE', BBL Culture swab REF-

220135, Becton, Dickinson and Company) were used to collect nares samples by rotating the dry swab

head in the nares for approximately 30 seconds from lab members, patients, or healthcare workers, and

then immediately placed in 95% EtOH. Eluent nucleic acid extractions were performed on 200 µL of the

swab eluent (either VTM or EtOH) using the Omega Mag-Bind® Viral DNA/RNA 96 Kit (catalog#

M6246-03), which only uses chemical lysis and does not include a bead beating step. For nucleic acid

extraction from the swab head, the MagMAX Microbiome Ultra kit (Cat#A42357, Thermo Fisher

Scientific) was used. For the direct comparison of SARS-CoV-2 extraction efficiency, we extracted EtOH

eluent and swab separately from the same samples of COVID-19 patients with approval of the UC San

Diego Institutional Review Board under protocols #150275 and #200613

Patient and hospital environmental sampling

All study patients were diagnosed and hospitalized with COVID-19 with approval of the UC San Diego

Institutional Review Board under protocols #150275 and #200613. Both nasal samples and hospital

surfaces were collected using three unmoistened swab types (PE, TMI, CGp; see Table 1). Nasal samples

were collected by inserting the swab into one nostril to the depth of approximately 2-3 cm and rotated for

5-10 seconds. Hospital surfaces sampled included the floor inside the patient's room (approximately 1x1

square foot area) and the patient's bedrail. All swabs were immediately placed in a collection tube

containing 0.5-1 mL 95% ethanol and stored on dry ice and processed for RNA or total nucleic acid

extraction (Supplementary Methods).

RT-qPCR for VTM and 95% EtOH comparison using polyester-tipped plastic swabs

SARS-CoV-2 detection was performed following a slightly miniaturized version of the CDC protocol.

Each RT-qPCR reaction contained 4μl RNA template, 100nm forward and reverse primers, 200nm probe,

3μl TaqPath (catalog# A15299, Thermo), and RNAse free water to a total reaction volume of 10μl. All

primers and probes were ordered from IDT (catalog# 10006606). RT-qPCR was performed on the Bio-

rad CFX384 Touch Real-Time PCR Detection System following the CDC thermocycling guidelines.

Serial dilutions of the Hs_RPP30 Positive Control plasmid (catalog# 10006626, IDT) or 2019-

nCoV_N_Positive Control   plasmid (catalog# 10006625, IDT) were included to extrapolate human

RNAse P and SARS-CoV-2 copy numbers, respectively.

Alternative swab list

Six swab types were used: sterile polyester-head, plastic-shaft ('PE', BBL Culture swab REF-220135,

Becton, Dickinson and Company); sterile foam-head, plastic-shaft ('BDF', Flock PurFlock REF-25-3606-

U-BT, Becton, Dickinson and Company); non-sterile cotton-head, plastic-shaft in use by The Microsetta

Initiative ('TMI', SKU#839-PPCS, Puritan Medical Products); non-sterile cotton-head plastic-shaft

consumer-grade ('CGp' Part #165902, CVS Caremark Corp.); non-sterile cotton-head wooden-shaft

consumer-grade ('CGw', Part#858948, CVS Caremark Corp.); and non-sterile cotton-head, wooden-shaft

('Pu', REF-806-WC, Puritan Medical Products).

Controls for RNA extraction efficiency testing

Approximately 600 ng of purified, DNA-free human lung RNA (Cat#AM7968, Thermo Fisher Scientific)

was pipetted onto each of the six swab types in triplicate and stored in two storage solutions (500 μL 95%

ethanol (EtOH) and 500 μL 91% isopropanol). Two sets of six, 10-fold serial dilutions of human RNA

were included as controls. The same quantity of RNA (600 ng) was added to either 95% EtOH (n=6) or

91% isopropanol (n=6) in the presence of 25 μg RNaseA to determine the resistance offered against

RNase contaminants. Four negative (swab only) and four positive (swab + 500 ng spiked human RNA + 5

μL spiked SARS-CoV-2 RNA ~20,000 copies per ul) controls were included, in addition to three, 10-fold

serial dilutions of this mixture in 95% EtOH.

Extraction and RT-qPCR of hospital swabs and controls

All samples were processed according to the manufacturer's protocol using the MagMAX Microbiome

Ultra kit (Cat#A42357, Thermo Fisher Scientific) and eluted into 70 μL buffer. For RT-qPCR, 5 μL

sample was processed in duplicate with averaged Ct values, using the standard SARS-CoV-2 protocol

provided by the CDC (Cat# 2019-nCoVEUA-01[15]). Both the swab head and 200 μL of eluent were

processed for nasal samples, but only the swab head was processed for floor, bedrail and spiked control

samples using the same methods.

Statistics and visualizations

Visualizations and statistical comparisons performed using PRISM 8.0 and the limit of detection

determination were consistent with CDC recommendations whereby samples with a Ct value greater than

40 are omitted [16].

 Supplementary Figures Legends

 Supplemental S1. Impacts of storage solution or swab type on RNA quality as measured by RNA

 Tapestation High Sensitivity kit. a) All direct-swab extracted RNA grouped by storage buffer and swab

 type. b) Samples grouped by storage buffer, no significant difference in RNA integrity number (RIN)

 values between storage buffers (95% EtOH vs. 91% isopropanol) (Mann-Whitney). c) Swab extracts

 grouped by swab type only and compared to determine if swab type has an impact on RNA quality

 (Kruskal-Wallis test).

 Supplemental Figure S2. Impacts of sample-type (eluent vs. swab head) on RNA recovery by swab

 used. Comparison human RNA recovery across six swab types (PE=polyester 'commercial', BDF=BD

 foam 'commercial', TMI=BD TMI 'commercial', CGp=plastic 'consumer grade', Pu=Puritan

 'commercial', CGw=wood 'consumer grade'), **a)** extracted from 200 μL eluent or **b)** swab head (Group

 comparison using Kruskal-Wallis)

 Supplemental Figure 3. Demonstration of impact of swab or storage buffer on human RNA and

 SARS-CoV-2 detection. a) Positive (swab + SARS-CoV-2 RNA + human RNA, n=4) and negative

 (swab only, n=4) controls from hospital processing experiment. **b)** Serial dilution of positive controls in

 95% EtOH to demonstrate conserved extraction efficiency across biomass. Three swab types:circle-PE,

 square=CGp, triangle=TMI.

 Supplemental Figure 4. Hospital built environment and patient screen for SARS-CoV-2.

 Demonstration of consumer-grade CGp and bulk TMI swab congruence compared to CDC polyester in a

 hospital setting across ten patient rooms and three sampling environments (bedrail, floor, and nasal swab)

 including negative and positive controls. Samples positive (+, dark blue background) or negative (-,

 orange background) for N1, N2, and Rp by CDC guidelines. Samples positive for N1 and Rp, but

 negative for N2 are labeled inconclusive for N2 (I-N2, blue) but considered positive for comparisons.

Samples positive for N2 and Rp, but negative for N1 (I-N1, light blue) are inconclusive. Samples not

measured for a given patient are labeled as NaN (light grey). All data except controls are identical to

those in Figure 1g.

Supplementary Figures

Supplemental S1. Impacts of storage solution or swab type on RNA quality as measured by RNA

Tapestation High Sensitivity kit.

Supplemental Figure S2. Impacts of sample-type (eluent vs. swab head) on RNA recovery.

Supplemental Figure 3. Demonstration of impact of swab or storage buffer on human RNA and

SARS-CoV-2 detection.

Supplemental Figure 4. Hospital built environment and patient screen for SARS-CoV-2.

		Experimental						Hospital (Built Environment)						Hospital (patient)					
		- controls			+ controls			bedrail			floor			nasal (swab)			nasal (Eluent)		
Room	Hospital	PE	TMI	CGp	PE	TMI	CGp	PE	TMI	CGp	PE	TMI	CGp	PE	TMI	CGp	PE	TMI	CGp
1	+	-	-	-	+	+	+	-	-	-	+	+	I-N2	+	+	+	I-N2	+	+
2	-	-	-	-	+	+	+	-	-	-	+	+	+	I-N1	I-N1	+	-	+	-
3	-	-	-	-	+	+	+	-	-	-	-	+	-	NaN	-	-	NaN	-	-
4	+	-	-	-	+	+	+	-	-	I-N2	-	-	-	NaN	-	-	NaN		
5	+	-	-	-	+	+	+	-	-	-	I-N1	+	+	NaN	+	+	NaN	-	-
6	+	-	-	-	+	+	I-N2	-	-	-	I-N1	+	+	NaN	+	-	NaN	-	-
7	+	-	-	-	I-N2	+	I-N2	I-N2	-	-	I-N2	+	I-N2	I-N2	NaN	I-N2	-	NaN	-
8	+	-	-	-	I-N2	I-N2	-	I-N2	I-N2	I-N2	I-N2	-	I-N2	+	NaN	+	I-N2	NaN	I-N2
9	-	NaN	-	NaN	NaN	NaN	NaN	-	-	-	I-N2	-	-	-	-	NaN	-	-	NaN
10	+	NaN	NaN	NaN	NaN	NaN	NaN	I-N2	I-N2	I-N2	I-N2	+	I-N2	+	NaN	+	I-N2 (low)	NaN	+